论文部分内容阅读
目的 :探讨mdm2癌基因蛋白在骨巨细胞瘤 (GCT)的表达及与GCT病理分级和临床良恶性的关系。方法 :应用SP免疫组织化学方法检测mdm2在 5 2例GCT(GCT按Jaffe分级 :Ⅰ级 15例、Ⅱ级 2 5例、Ⅲ级 12例 )中的表达。结果 :18例mdm2表达呈阳性 ,占 34 .6 % ,在Ⅰ～Ⅲ级中的阳性表达率分别为 40 .0 %、32 .0 %、33.3% ,mdm2阳性表达率在骨巨细胞瘤Ⅰ～Ⅲ级中的差异无显著性意义 (χ2 =0 .2 8,P >0 .0 5 )。在良性、可疑恶性和恶性中的阳性表达分别为 15 .0 %、35 .3%、6 0 .0 % ,mdm2阳性表达率在骨巨细胞瘤良恶性中的差异有显著性意义 (χ2 =7.6 7,P <0 .0 5 )。结论 :mdm2在GCT中的表达与病理分级无关而与其临床良恶性程度有关。
Objective: To investigate the relationship between the expression of mdm2 oncogene protein in giant cell tumor of bone (GCT) and the pathological grading and clinical benign and malignant lesions of GCT. Methods: SP immunohistochemistry was used to detect the expression of mdm2 in 52 cases of GCT (GCT by Jaffe classification: Ⅰ grade 15 cases, Ⅱ 25 cases, Ⅲ grade 12 cases). Results: The positive expression rates of mdm2 in 18 cases were 34.6%. The positive expression rates of mdm2 in grade Ⅰ ~ Ⅲ were 40.0%, 32.0% and 33.3% There was no significant difference in grade Ⅲ ~ Ⅲ (χ2 = 0.28, P> 0.05). The positive expression rates of mdm2 in benign and suspected malignant and malignant tumors were 15.0%, 35.3% and 60.0%, respectively. There was a significant difference in the expression of mdm2 between benign and malignant giant cell tumor (χ2 = 7.6 7, P <0. 05). Conclusion: The expression of mdm2 in GCT has nothing to do with the pathological grade, but related with its clinical benign and malignant degree.